Infectious diseases now最新文献

{"title":"HLA-A*03 may confer protection against long COVID through an enhanced immune response","authors":"Eduardo Pons-Fuster ,&nbsp;Rodrigo Martinez-Rodriguez ,&nbsp;Lourdes Gimeno-Arias ,&nbsp;M.J. Alcaraz ,&nbsp;Marta Moreno ,&nbsp;Jose M. Gómez ,&nbsp;Ana Pelaez ,&nbsp;Elisa García ,&nbsp;Cristina Tomás ,&nbsp;Angeles Muñoz ,&nbsp;María V. Martínez-Sánchez ,&nbsp;Inmaculada Ruiz-Lorente ,&nbsp;Diana Ceballos ,&nbsp;Alfredo Minguela ,&nbsp;Enrique Bernal","doi":"10.1016/j.idnow.2025.105057","DOIUrl":"10.1016/j.idnow.2025.105057","url":null,"abstract":"<div><h3>Background</h3><div>The COVID-19 pandemic has led to widespread infection, with a significant subset of patients developing persistent symptoms known as Long COVID. Understanding the genetic factors influencing Long COVID susceptibility and severity is crucial for development of targeted interventions.</div></div><div><h3>Objective</h3><div>This study aimed to evaluate the impact of HLA alleles, KIR receptors, and their interactions on the development of Long COVID in patients from southeastern Spain having contracted COVID-19 during the early 2020 pandemic wave.</div></div><div><h3>Methods</h3><div>A cross-sectional prospective study enrolled 153 COVID-19 patients. Three months post-infection, HLA-A, –B, –C, KIR genotyping and immunological variables were analyzed using serum and blood samples. Long COVID was diagnosed three years post- infection based on persistent symptoms.</div></div><div><h3>Results</h3><div>Among the participants, 71 developed Long COVID. HLA-A*03 was less frequent in Long COVID compared to non-Long COVID patients (10.7 % vs. 30.5 %, p = 0.001). Patients with HLA-A*03 had a higher percentage of CD8⁺ T cells than patients with other allotypes (33.6 ± 13.4 % vs 28.7 ± 10.8 %, p = 0.033) and showed lower expression of KIR2DL1(1265 ± 547 vs 1465 ± 414 MFI, p = 0.031) and KIR3DL1 (300.6 ± 125.0 vs 398.9 ± 131.0 MFI, p = 0.047). Moreover, NK cells in HLA-A*03 patients showed lower expression of the TIGIT inhibitory receptor (73.7 ± 12.2 % vs 78.2 ± 10.8 %, p = 0.046).</div></div><div><h3>Conclusion</h3><div>HLA-A*03 may play a protective role against Long COVID, potentially through enhanced immune responses involving CD8⁺ T cells and NK cells. Further research in larger, diverse cohorts is needed to validate these findings and to refine personalized medicine strategies for managing COVID-19 sequelae.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 4","pages":"Article 105057"},"PeriodicalIF":2.9,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143654693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early suPAR levels as a predictor of COVID-19 severity: A new tool for efficient patient triage","authors":"Pauline Nègre ,&nbsp;Didier Tayac ,&nbsp;Thibaut Jamme ,&nbsp;Marie-Sophie Combis ,&nbsp;Françoise Maupas-Schwalm","doi":"10.1016/j.idnow.2025.105058","DOIUrl":"10.1016/j.idnow.2025.105058","url":null,"abstract":"<div><h3>Background</h3><div>Following several waves of the COVID-19 pandemic, we are now facing a lower but persistent rate of SARS-CoV-2 infections, with seasonal resurgences often coinciding with other respiratory tract infections.</div></div><div><h3>Objective</h3><div>We aimed to identify early clinico-biological variables predictive of an unfavorable outcome in patients with primary SARS-CoV-2 infection. We also evaluated the role of suPAR, an innovative biomarker, in predicting disease severity.</div></div><div><h3>Methods</h3><div>We included 255 patients with PCR-confirmed primary SARS-CoV-2 infection and with a 30-day follow-up minimum. Blood samples were collected within the first 24 h of hospitalization to measure suPAR levels. Comprehensive data from medical records were analyzed to assess their predictive value in stratifying patients into seven severity groups, with groups 1 to 3 representing severe COVID-19 (death, intubation, ECMO, or non-invasive ventilation).</div></div><div><h3>Results</h3><div>Early plasma suPAR levels were significantly associated with severe disease progression, as evidenced by ANOVA and logistic regression models, highlighting suPAR as a persistent predictive factor for unfavorable outcomes.</div></div><div><h3>Conclusion</h3><div>Our findings suggest that a single suPAR measurement, performed early after a positive PCR test for SARS-CoV-2, holds strong predictive value for patient outcomes. This biomarker, alongside pulse oximetry and CT scan results, could be instrumental in early patient triage during seasonal COVID-19 resurgences.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 4","pages":"Article 105058"},"PeriodicalIF":2.9,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143654691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccination coverage against three viral sexually transmitted diseases, among 18-to-30-year-olds seen between May 2023 and May 2024 in the Martinique University Hospital CeGIDD","authors":"L. Lefèvre ,&nbsp;F. Quenard ,&nbsp;O. Cabras ,&nbsp;E. Medo ,&nbsp;T.A. Barry ,&nbsp;A. Cabié ,&nbsp;L. Cuzin","doi":"10.1016/j.idnow.2025.105055","DOIUrl":"10.1016/j.idnow.2025.105055","url":null,"abstract":"<div><h3>Objective and Methods</h3><div>: We retrospectively assessed protection against HBV (defined by HBs Ab &gt; 10 UI/L), HAV (defined by positive IgG), and HPV (defined by at least one shot) in 1161 patients aged 18–––30 years old who consulted at an HIV and STI screening center (CeGIDD) between May 2023 and May 2024. Results are presented by gender, sexual orientation and PrEP use.</div></div><div><h3>Results</h3><div>All in all, 59% (621/1051) of the population was HBV-immune. Among MSM, bisexual men and transgender people, 17% (18/105) were HAV-immune, a proportion rising to 40% (42/105) at the end of the study period. Among PrEP patients, 18% (13/78) were HAV-immune and 64% (50/78) were HBV-immune. HPV vaccination was given to 12% (68/569) of women, 13% (72/583) of men, 37% (54/147) of MSM, bisexual men and transgender patients, and to 41% (32/78) of PrEP users.</div></div><div><h3>Conclusion</h3><div>All health workers should be fully aware of the relevant recommendations and actively involved in enhancing patient protection.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 3","pages":"Article 105055"},"PeriodicalIF":2.9,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143628644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antimicrobial activity of new anti-Pseudomonas beta-lactam-beta-lactamase inhibitors against Pseudomonas aeruginosa respiratory isolates recovered during the study for Monitoring Antimicrobial Resistance Trends (SMART) program in France (2016–2022)","authors":"Charlie Zins ,&nbsp;Hélène Pailhoriès ,&nbsp;Rachel Chenouard ,&nbsp;Stéphane Corvec ,&nbsp;Sandrine Dahyot ,&nbsp;Paul-Louis Woerther ,&nbsp;Catherine Eckert ,&nbsp;Gautier Pierrat ,&nbsp;Xavier Bourge ,&nbsp;Sophie Boyer ,&nbsp;Marie Kempf","doi":"10.1016/j.idnow.2025.105056","DOIUrl":"10.1016/j.idnow.2025.105056","url":null,"abstract":"<div><h3>Objectives</h3><div>To assess the susceptibility of ceftolozane/tazobactam (C/T) and comparators to <em>Pseudomonas aeruginosa</em> isolates recovered from respiratory-tract-infections (RTI) between 2016–2022 in the French SMART study.</div></div><div><h3>Methods</h3><div>Antibiotic susceptibility testing and minimum inhibitory concentrations (MICs) of 717 <em>P.aeruginosa</em> isolates collected in five French hospitals were determined and interpreted according to the EUCAST-2022 guidelines. <em>P. aeruginosa</em> isolates resistant (R) to imipenem and/or C/T were screened by PCR for extended-spectrum-β-lactamases (ESBLs), AmpC and carbapenemase genes. The identified genes were sequenced and the variants determined.</div></div><div><h3>Results</h3><div>All in all, 96.5 % of <em>P. aeruginosa</em> isolates were susceptible to C/T, comparable to the susceptibilities of meropenem-vaborbactam (MVB = 96.5 %), imipenem/relebactam (IMI/REL = 96.9 %) and ceftazidime-avibactam (C/A = 97.0 %). MIC₅₀ and MIC₉₀ for C/T were 0.5 and 2 mg/L respectively against the 717 isolates. Among the 242 isolates (33.7 %) resistant to at least one anti-<em>Pseudomonas</em> β-lactam, close to 90 % were susceptible to C/T, C/A, MVB and IMI/REL. Among the 80 isolates resistant to piperacillin-tazobactam, cefepime and ceftazidime, 76.3 % were susceptible to C/T and only IMI/REL and amikacin reached susceptibility exceeding 80 %. Among the 32 isolates resistant to imipenem and meropenem, susceptibility exceeding 60 % was observed only for IMI/REL, C/T, and C/A. For these strains, the MIC₅₀ of C/T was 2 mg/L, while that of C/A was at the resistance threshold (8 mg/L). IMI/REL had the strongest activity (72 %) against the 25 isolates resistant to C/T. Lastly, 53 imipenem and/or C/T-R isolates harbored a class C β-lactam (<em>bla</em>PDC) variant, and one of them also carried the <em>bla</em>_PER-1 gene and another, the <em>bla</em>_VIM-2 gene.</div></div><div><h3>Conclusion</h3><div>C/T is a reliable treatment option in RTI caused by <em>P. aeruginosa</em>.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 4","pages":"Article 105056"},"PeriodicalIF":2.9,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imported loiasis: Diagnostic and therapeutic challenges","authors":"C. Elouardi ,&nbsp;A. Lefort ,&nbsp;L. Deconinck ,&nbsp;N. Peiffer-Smadja ,&nbsp;S. Houzé ,&nbsp;N. Argy","doi":"10.1016/j.idnow.2025.105053","DOIUrl":"10.1016/j.idnow.2025.105053","url":null,"abstract":"<div><div>Loiasis is a vector-borne parasitic disease that has long been neglected due to its benign nature and its geographical distribution, which is restricted to the forest regions of Central and West Africa. However, it is now recognized as a significant public health concern in endemic areas, where chronically infected patients face organ damage and an increased risk of mortality. Loiasis presents several challenges, from diagnosis to treatment, as inappropriate therapies can lead to severe and at times fatal side effects.</div><div>Although loiasis has low prevalence in Europe, historical connections with most endemic countries expose the continent to a high risk of imported cases, making it the most commonly imported filariasis in Europe. Population movements challenge healthcare providers, who often struggle with limited diagnostic and therapeutic tools. It is therefore essential to adopt an appropriate approach aimed at optimizing to optimize patient management and preventing severe adverse effects due to inappropriate treatment.</div><div>At present, however, there exist no specific recommendations for managing imported loiasis. The present review aims to evaluate the current state of knowledge on its management and to propose an optimal approach through a decision-making algorithm, emphasizing pathophysiology by patient category, biological diagnostic methods and perspectives, as well as therapeutic strategies adapted to the challenges of non-endemic areas. These updated data aim to help clinicians from non-endemic areas to improve management of imported loiasis through development of a decision-making algorithm.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 3","pages":"Article 105053"},"PeriodicalIF":2.9,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The neutrophil-to-lymphocyte ratio in bronchoalveolar lavage fluid could help to personalize corticosteroid therapy in severe COVID-19 pneumonia","authors":"Nausicaa Beaudequin ,&nbsp;Benjamin Glemain ,&nbsp;Anne Fajac ,&nbsp;Vincent Rothstein ,&nbsp;Muriel Fartoukh ,&nbsp;Guillaume Voiriot","doi":"10.1016/j.idnow.2025.105054","DOIUrl":"10.1016/j.idnow.2025.105054","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the response to high-dose corticosteroids according to bronchoalveolar neutrophil-to-lymphocyte ratio (BAL-NLR) in critically-ill COVID-19 patients.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed a single-center cohort of adult COVID-19 patients admitted to the intensive care unit with COVID-19 pneumonia between 2020 and 2022, who had a bronchoalveolar lavage and received systemic corticosteroids. We defined high-dose corticosteroid therapy as the administration of at least 1<!--> <!-->mg/kg/day of methylprednisolone.</div></div><div><h3>Results</h3><div>Among 161 patients, 56 had LOW_BAL-NLR (&lt;0.8), 55 MILD_BAL-NLR (0.8–3.5), and 50 HIGH_BAL-NLR (&gt;3.5). A quarter of patients received high-dose corticosteroid therapy. In the HIGH_BAL-NLR group, those receiving high-dose corticosteroid therapy had a lower (27 % versus 43 %, <em>p</em> = 0.23) 90-day mortality rate than those receiving a standard dose. In the LOW_BAL-NLR group, those receiving high-dose corticosteroid therapy had a higher (31 % versus 12 %, <em>p</em> = 0.12) 90-day mortality rate.</div></div><div><h3>Conclusion</h3><div>Our results suggest that bronchoalveolar cellular phenotype influences therapeutic response to high-dose corticosteroid therapy.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 3","pages":"Article 105054"},"PeriodicalIF":2.9,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Balancing AI accuracy and medical guidance: Evaluating ChatGPT’s role in UTI-related queries","authors":"Mohd Rafi Lone,&nbsp;Yuvraj Singh Naruka,&nbsp;S. Viswhanath,&nbsp;Adarsh Pandey","doi":"10.1016/j.idnow.2025.105051","DOIUrl":"10.1016/j.idnow.2025.105051","url":null,"abstract":"","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 3","pages":"Article 105051"},"PeriodicalIF":2.9,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143580307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for clinical treatment failure regarding carbapenem-resistant Enterobacterales in the southwestern United States","authors":"Michelle H. Ting,&nbsp;Mycah Martens,&nbsp;Haya Albazzaz,&nbsp;Christine Wolesensky,&nbsp;Emir Kobic","doi":"10.1016/j.idnow.2025.105052","DOIUrl":"10.1016/j.idnow.2025.105052","url":null,"abstract":"<div><h3>Background</h3><div>Rates of carbapenem resistant Enterobacterales (CRE)-related infections in the United States have continued to rise, leading to significant morbidity and mortality. <em>Klebsiella pneumoniae</em> carbapenemases (KPC) have been the most common carbapenemase in the United States; over time, however, a shift has occurred in some regions.</div></div><div><h3>Methods</h3><div>A multicenter, retrospective observational study was performed across a large-scale healthcare system of 33 acute care hospitals in the southwestern United States, primarily Arizona. Patients were included if they were ≥ 18 years old with resistance to at least one carbapenem from January 1st, 2023 to July 31st, 2023.</div></div><div><h3>Results</h3><div>Among 169 included patients, the most common CRE species was <em>Klebsiella pneumoniae</em> (82 %) with the most common identified carbapenemase being metallo beta lactamase (MBL) (76 %), the majority of which were New Delhi metallo-beta-lactamases (NDMs). Multivariable logistic regression was performed to determine risk factors for treatment failure regarding CRE infections. This model found renal replacement therapy [OR 2.44 (95 % CI 1.04–5.71)], prior hospitalization within 90 days of index culture [OR 2.69 (95 % CI 1.12–6.47), and admission to the ICU [OR 5.55 (95 % CI 2.58–11.93)] to be statistically significant risk factors for treatment failure.</div></div><div><h3>Conclusions</h3><div>Our study highlights the alarming rise of NDM-producing CRE’s in the southwestern US, primarily Arizona, along with the importance of closely assessing patient risk factors in view of deciding on appropriate empiric therapy.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 3","pages":"Article 105052"},"PeriodicalIF":2.9,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infectious complications after autologous hematopoietic stem cell transplantation for patients with an autoimmune indication: A protocol for a systematic review and meta-analysis","authors":"Carolin-Sophie Wagner ,&nbsp;Alexander Lithopoulos ,&nbsp;Risa Shorr ,&nbsp;Harold Atkins","doi":"10.1016/j.idnow.2025.105050","DOIUrl":"10.1016/j.idnow.2025.105050","url":null,"abstract":"<div><h3>Objectives</h3><div>Autologous hematopoietic stem cell transplantation (aHSCT) offers potential long-term remission for various autoimmune diseases, especially in patients unresponsive to conventional treatments. Notwithstanding its benefits, aHSCT carries risks from cytotoxic agents and temporary immunosuppression, leading to infectious complications. This systematic review focuses on the incidence and characteristics of infections in patients with autoimmune diseases undergoing aHSCT.</div></div><div><h3>Patients and methods</h3><div>Data will be collected from trials identified in a search across Medline, Embase, Cochrane Register of Controlled Trials, Web of Science, <span><span>clinicaltrials.gov</span><svg><path></path></svg></span>, and the International Clinical Trials Registry Platform. Eligible publications are any articles that include patients undergoing autologous hematopoietic stem cell transplantation where the primary indication is an autoimmune disease. Outcomes include infection characteristics, treatment-related and all-cause mortality, and the robustness and quality of infection reporting. Data screening, collection, and extraction will be conducted using Covidence. A narrative synthesis will describe the results, and meta-analysis will be performed if possible.</div></div><div><h3>Results and conclusions</h3><div>This systematic review aims to define the risk of infections during and after stem cell transplantation for patients with autoimmune diseases with the goal of improving prophylaxis, early detection and treatment of infectious complications.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 3","pages":"Article 105050"},"PeriodicalIF":2.9,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143562227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update of guidelines for management of community acquired pneumonia in adults by the French infectious disease society (SPILF) and the French-speaking society of respiratory diseases (SPLF). Endorsed by the French intensive care society (SRLF), the French microbiology society (SFM), the French radiology society (SFR) and the French emergency society (SFMU)","authors":"Aurélien Dinh ,&nbsp;François Barbier ,&nbsp;Jean-Pierre Bedos ,&nbsp;Mathieu Blot ,&nbsp;Vincent Cattoir ,&nbsp;Yann-Erick Claessens ,&nbsp;Xavier Duval ,&nbsp;Pierre Fillâtre ,&nbsp;Maxime Gautier ,&nbsp;Yann Guegan ,&nbsp;Sophie Jarraud ,&nbsp;Alban Le Monnier ,&nbsp;David Lebeaux ,&nbsp;Paul Loubet ,&nbsp;Constance de Margerie ,&nbsp;Philippe Serayet ,&nbsp;Yacine Tandjaoui-Lambotte ,&nbsp;Emmanuelle Varon ,&nbsp;Yves Welker ,&nbsp;Damien Basille","doi":"10.1016/j.idnow.2025.105034","DOIUrl":"10.1016/j.idnow.2025.105034","url":null,"abstract":"","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 2","pages":"Article 105034"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}